Using interactions between viral peptides and human proteins as a starting point, researchers from Enyo Pharma Inc., the University of Lyon and other institutions were able to bootstrap themselves to a mitochondria-targeting small molecule that showed activity in a mouse model of nonalcoholic steatohepatitis (NASH) with chronic kidney disease.
Jiangxi Jemincare Group Co. Ltd. has reported that its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., recently received approvals for clinical trials of five of its drugs in the fields of cancer, kidney and infectious diseases.
Arrowhead Pharmaceuticals Inc. has filed an application in New Zealand seeking clearance to initiate a phase I/IIa trial of ARO-CFB, the company’s investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for complement-mediated renal disease, such as immunoglobulin A nephropathy (IgAN).
Researchers from Taisho Pharmaceutical Co. Ltd. have reported initial evaluation of novel pyrazolylpyridine derivatives with increased selectivity for inhibition of the 20-hydroxyeicosatetraenoic acid (20-HETE) synthase CYP4A11/4F2, to be developed as candidates for the treatment of renal fibrosis.
Uromems SAS is seeking patent protection for a system for the control of an inflatable implant device with a variable volume fluid reservoir that may be used to plug an anatomical duct such as a urethra, gastric duct, colon, or rectum, or configured for use as a penile implant.
Awak Technologies Pte Ltd. gained the U.S. FDA’s breakthrough designation for an artificial intelligence (AI)-based kidney disease progression prediction (KDDP) model on Nov. 27, following its $20 million fundraising that marked one of Singapore’s largest med-tech financings in 2023.
Aria Pharmaceuticals Inc. has synthesized compounds acting as caspase-1 (IL-1β-converting enzyme) and pyroptosis inhibitors reported to be useful for the treatment of alopecia, autoimmune hemolytic anemia, chronic kidney disease, duodenal ulcer, hepatitis B, osteoarthritis, systemic lupus erythematosus and uveitis, among others.
Daiichi Sankyo Co. Ltd. and Kyoto Pharmaceutical Industries Ltd. have identified Kelch-like ECH-associated protein 1 (Keap1)/Nrf2 interaction inhibitors reported to be useful for the treatment of acute lung injury, chronic kidney disease, autism, Alzheimer's disease, dry eye, heart failure, psoriasis and Sjögren's syndrome, among others.
RSS
